AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E399767-T1: [Translated] 1-PHENYL AND 1-PYRIDYLPYRAZOLE DERIVATIVES AND THEIR USE AS PESTICIDES

Chemical patent from PubChem database. Patent Number: AT-E399767-T1. Title: Method of Treatment Using Chemical Compounds. Filing Date: 1995-07-14. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: Methods for treating diseases using specific chemical compounds are provided, including dosing regimens and combination therapies for enhanced therape... IPC Classifications: C12N, C12P, A61K. This patent covers 38 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E401251-T1: [Translated] METHOD AND DEVICE FOR LABELING

In a method for labeling, a label strip (20) is moved by means of an electric motor (80). Arranged on this label strip are labels (26) of predetermined length (EL) with uniform interstices (SB). The motor has associated with it a position controller (218), also a sensor (44) for sensing a predetermined position of a label (26) when the latter is moved on the label strip (20) relative to the sensor (44). The method has the following steps: in accordance with a stored profile, the label strip (20) is set in motion beginning from a start position (A), a first target position (Z) of the label strip being specified to the position controller (218); during the motion of the label strip (20), a predetermined position (M) of the label strip (20) is sensed; and subsequently thereto, a revised target position (Z) is specified to the position controller (218). This makes possible fast and precise labeling, since the target position can be reached very accurately. A corresponding device has a compact design.
Children’s Bureau Regional Program Managers

CBRegion1@acf.hhs.gov - please use for grantee plan submissionsAmy LockhartAmy.Lockhart@acf.hhs.govJFK Federal Building, Rm. 200015 Sudbury StreetBoston, MA 02203(617) 565-1135States:  Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont

CBRegion2@acf.hhs.gov - please use for grantee plan submissionsShari BrownShari.Brown@acf.hhs.gov26 Federal Plaza, Rm. 4114New York, NY10278(646) 905-8217States and Territories:  New Jersey, New York, Puerto Rico, Virgin Islands

CBRegion3@acf.hhs.gov - please use for grantee plan submissionsEvan SteelEvan.Steel@acf.hhs.govThe Strawbridge Building801 Market StreetPhiladelphia, PA 19107-3134(215) 861-4013States:  Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia

CBRegion4@acf.hhs.gov - please use for grantee plan submissionsDianne KellyDianne.Kelly@acf.hhs.gov61 Forsyth Street SW, Ste. 4M60Atlanta, GA 30303-8909(404) 562-2781States: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee

CBRegion5@acf.hhs.gov - please use for grantee plan submissionsCindy LowderCindy.Lowder@acf.hhs.govRalph H. Metcalfe Federal Building77 West Jackson Boulevard, 21st FloorChicago, IL 60604(312) 886-4918States: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin

CBRegion6@acf.hhs.gov - please use for grantee plan submissionsCory McCarrellCory.McCarrell@acf.hhs.gov1301 Young Street, Suite 106-1060Dallas, TX 75202-5433(214) 767-1971States: Arkansas, Louisiana, New Mexico, Oklahoma, Texas

CBRegion7@acf.hhs.gov - please use for grantee plan submissionsKendall DarlingKendall.Darling@acf.hhs.govFederal Office Building, Room 349601 E. 12th StreetKansas City, MO 64106(816) 426-2262States: Iowa, Kansas, Missouri, Nebraska

CBRegion8@acf.hhs.gov - please use for grantee plan submissionsMarilyn KennersonMarilyn.Kennerson@acf.hhs.gov1961 Stout Street, 8th FloorByron Rogers Federal BuildingDenver, CO 80294-3538(303) 844-1163States: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming

CBRegion9@acf.hhs.gov - please use for grantee plan submissionsSharon KingSharon.King@acf.hhs.gov90 7th Street - Ste 9-300San Francisco, CA 94103(415) 437-8513States and Territories: Arizona, California, Hawaii, Nevada, Outer Pacific—American Samoa Commonwealth of the Northern Marianas, Federated States of Micronesia (Chuuk, Pohnpei, Yap), Guam, Marshall Islands, Palau

CBRegion10@acf.hhs.gov - please use for grantee plan submissionsNadia NijimNadia.Nijim@acf.hhs.gov701 Fifth Avenue, Suite 1600, MS-73Seattle, WA 98104(206) 615-3682States: Alaska, Idaho, Oregon, Washington

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525263: N''-Propyl-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 1,1,3,3-tetramethyl-2-propylguanidine. Molecular Formula: C8H19N3. Molecular Weight: 157.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528369: Nornicotine, N-formyl

Chemical compound data from PubChem database. IUPAC Name: 2-pyridin-3-ylpyrrolidine-1-carbaldehyde. Molecular Formula: C10H12N2O. Molecular Weight: 176.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled more closely those used in most catheterization laboratories than did the two previous randomized trials comparing ticlopidine and clopidogrel. The results of the TOPPS trial support the current practice of substituting ticlopidine for clopidogrel in stent patients.
Compound 528805: [3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] decanoate

Chemical compound data from PubChem database. IUPAC Name: [3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] decanoate. Molecular Formula: C30H48O2. Molecular Weight: 440.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Stage-specific changes in fetal thymocyte proliferation during the CD4

Background
          The function of the thymic microenvironment is to promote thymocyte maturation, in part via regulation of thymocyte proliferation and cell death. Defects in fetal thymic epithelial cell (TEC) development and function, and therefore in the formation of a functional microenvironment, can be caused either directly by TEC differentiation defects or indirectly by defective thymocyte maturation. In this paper we studied fetal thymocyte proliferation during the early transition from the CD3-4-8- (triple negative, TN) to CD4+8+ (double positive, DP) stages. We compared wild type mice with Rag1-/- mice and with Hoxa3+/-Pax1-/- compound mutant mice, which have blocks at different stages of thymocyte development.
        
        
          Results
          Wild type fetal and adult thymus showed stage-specific differences in the proliferation profiles of developing thymocytes, with fetal stages showing generally higher levels of proliferation. The proliferation profile of fetal thymocytes from Rag1-/- mutants also had stage-specific increases in proliferation compared to wild type fetal thymocytes, in contrast to the lower proliferation previously reported for thymocytes from adult Rag1-/- mutants. We have previously shown that Hoxa3+/-Pax1-/- mice have abnormal fetal TEC development, resulting in increased apoptosis at the TN to DP transition and decreased DP cell numbers. Fetal thymocytes from Hoxa3+/-Pax1-/- compound mutants had increased proliferation, but fewer proliferating cells, at the DP stage. We also observed a decrease in the level of the cytokines IL-7 and SCF produced by Hoxa3+/-Pax1-/-TECs.
        
        
          Conclusion
          Our results indicate complex and stage-specific effects of abnormal TEC development on thymocyte proliferation.
Hepatitis C: Commercial Laboratory Residual Sera, November 2023–September 2024

This dataset provides hepatitis C virus antibody and RNA test results from all 50 states and the District of Columbia using a convenience sample of de-duplicated, deidentified residual serum specimens from a large commercial laboratory. Specimens were collected for any routine clinical screening or diagnostic testing purposes and were tested for hepatitis C virus during November 2023 through September 2024 proportional to the percent of the U.S. population in each jurisdiction and stratified by two age groups (18–≤49 years and 50–≤75 years) within sex. Specimens with reactive or equivocal hepatitis C virus antibody results were reflexed to HCV RNA testing. These data underly the manuscript published in Clinical Infectious Diseases, “Estimated hepatitis C prevalence and viral clearance using residual sera from a large commercial laboratory — November 2023–September 2024” (doi 10.1093/cid/ciag007).

Data Limitations:
1. Generalizability. Persons who had blood drawn for routine screening or clinical care by a single commercial laboratory might not be representative of the general U.S. adult population.
2. Convenience sampling is subject to potential biases.
3. Specimens from carceral facilities or incarcerated persons are not representative of the overall carceral population in the United States; carceral specimens are overrepresented from some jurisdictions and underrepresented from others.
2010 CMHS Uniform Reporting System (URS) Output Tables for Oregon

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527823: 3-Cyclohexene-1-methanol, 2-hydroxy-alpha,alpha,4-trimethyl-

Chemical compound data from PubChem database. IUPAC Name: 6-(2-hydroxypropan-2-yl)-3-methylcyclohex-2-en-1-ol. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Cost Report Audited Data Print Image: 2015

This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/
Compound 528238: 2-Methyl-5-propyltetrahydrothiophene

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-5-propylthiolane. Molecular Formula: C8H16S. Molecular Weight: 144.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529742: Methyl 4,5-dibromo-2-chloro-3-oxopentanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 4,5-dibromo-2-chloro-3-oxopentanoate. Molecular Formula: C6H7Br2ClO3. Molecular Weight: 322.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
State Participation in the Medicaid Expansion Provision of the Affordable Care Act: Implications for Uninsured Individuals with a Behavioral Health Condition

This is a Center for Behavioral Health Statistics and Quality (CBHSQ) short report examining lack of insurance rates among individuals with a behavioral health disorder in states that expanded Medicaid eligibility, did not expand Medicaid eligibility, and are undecided.  It uses 2009-2013 data from the National Survey on Drug Use and Health (NSDUH).
Compound 527747: 2,2,2-Trichloroethyl pentadecanoate

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl pentadecanoate. Molecular Formula: C17H31Cl3O2. Molecular Weight: 373.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Biphasic positive airway pressure ventilation (PeV+) in children

Background:
          Biphasic positive airway pressure (BIPAP) (also known as PeV+) is a mode of ventilation with cycling variations between two continuous positive airway pressure levels. In adults this mode of ventilation is effective and is being accepted with a decrease in need for sedatives because of the ability to breathe spontaneously during the entire breathing cycle. We studied the use of BIPAP in infants and children.
        
        
          Methods:
          We randomized 18 patients with respiratory failure for ventilation with either BIPAP (n = 11) or assisted spontaneous breathing (ASB) (n = 7) on Evita 4. Lorazepam and, if necessary, morphine were used as sedatives and adjusted in accordance with the Comfort scale. We compared number of randomized mode failure, duration and complications of ventilation and number and dosages of sedatives administered.
        
        
          Results:
          No differences in patient characteristics, ventilatory parameters, complications of ventilation or use of sedatives were noted. Ten out of eleven patients that we intended to ventilate with BIPAP were successfully ventilated with BIPAP. Four out of seven patients that we intended to ventilate with ASB could not be ventilated adequately with ASB but were successfully crossed over to BIPAP without the need for further sedatives.
        
        
          Conclusions:
          BIPAP is an effective, safe and easy to use mode of ventilation in infants and children.
Response ofEscherichia colicontaining mycobacterial carotene genes to UV radiation

Carotenoid pigments are largely distributed in nature. They are
present in all of the photosynthetic organisms as well as in some bacteria, fungi, and yeast [1]. Two major biological roles have been assigned to carotenoids in plants and prokaryotes. In photosynthetic organisms, these pigments are involved in trapping light energy. A more general role applicable to both photosynthetic and non-photosynthetic cell, is protection from photodynamic action [1]. Genes controlling the synthesis of these pigments have been studied in several organisms such asErwiniaspecies [2,3,4],Mycobacterium aurumA+[5,6],Arabidopsis[7,8],Xantophyllomyces dendrorhous[9] andBrevibacterium linens[10].
United States (US)

This report presents the United States\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the United States for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 525129: beta-Gentiobiose octamethyl

Chemical compound data from PubChem database. IUPAC Name: 2,3,4,5-tetramethoxy-6-[[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxymethyl]oxane. Molecular Formula: C20H38O11. Molecular Weight: 454.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526626: 8-(3-Hydroxy-2-methoxypropyl)-2-oxochromene-3-carboxylic acid

Chemical compound data from PubChem database. IUPAC Name: 8-(3-hydroxy-2-methoxypropyl)-2-oxochromene-3-carboxylic acid. Molecular Formula: C14H14O6. Molecular Weight: 278.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Financial Empowerment Toolkit

The Financial Empowerment Toolkit for Youth and Young Adults in Foster Care, developed by the Department of Health and Human Services’ Administration on Children, Youth and Families and the Office of Community Services, is designed to provide caseworkers, Independent-Living skills providers, foster parents and other supportive adults with strategies and resources to critically evaluate and improve their ability to promote the financial capabilities of youth in foster care. The toolkit is a compilation of lessons learned, best practices and practical tools, which can be used together or separately. It is aimed at those working with youth under the age of 18 and young adults preparing to transition out of foster care, and the content and tools can be tailored to meet stakeholder needs based on the intended outcomes of their services and the characteristics of the populations they serve.

The toolkit includes the following resources:

Metadata-only record linking to the original dataset. Open original dataset below.
NCHS Survey Data Linked to United States Renal Data System (USRDS) End-Stage Renal Disease Files

NCHS has linked data from various surveys with End Stage Renal Disease (ESRD) data obtained from the United States Renal Data System (USRDS). Linkage of the data from NCHS survey participants with the USRDS ESRD data provides the opportunity to study changes in health status and health care utilization among patients diagnosed with ESRD.
Expression and localization of estrogen receptor-β in annulus cells of the human intervertebral disc and the mitogenic effect of 17-β-estradiol in vitro

Background
          Recent evidence suggests that estrogens exert effects in different tissues throughout the body, and that the estrogen receptor β (ERβ) may be important for the action of estrogen (17-β-estradiol) on the skeleton. The cellular localization of ERβ in the human intervertebral disc, however, has not yet been explored.
        
        
          Methods
          Human disc tissue and cultured human disc cells were used for immunocytochemical localization of ERβ. mRNA was isolated from cultured human disc cells, and RT-PCR amplification of ERβ was employed to document molecular expression of this receptor. Cultured human disc cells were tested to determine if 17-β-estradiol stimulated cell proliferation.
        
        
          Results
          In this report data are presented which provide evidence for ERβ gene expression in human intervertebral disc cells in vivo and in vitro. Culture of annulus cells in the presence of 10-7 M 17-β-estradiol significantly increased cell proliferation.
        
        
          Conclusions
          These data provide new insight into the biology of cells in the annulus of the intervertebral disc.
AH Provisional COVID-19 Deaths by HHS Region, Race, and Age, 2015-2021

Provisional deaths involving coronavirus disease 2019 (COVID-19) and deaths from all causes reported to NCHS by week the death occurred, HHS region of occurrence, race and Hispanic origin, and age group (0-24, 25-64, 65+ years), from 2015-2021.

United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.
Potential antimutagenic activity of berberine, a constituent of

Background
          As part of a study aimed at developing new pharmaceutical products from natural resources, the purpose of this research was twofold: (1) to fractionate crude extracts from the bark of Mahonia aquifolium and (2) to evaluate the strength of the antimutagenic activity of the separate components against one of the common direct-acting chemical mutagens.
        
        
          Methods
          The antimutagenic potency was evaluated against acridine orange (AO) by using Euglena gracilis as an eukaryotic test model, based on the ability of the test compound/fraction to prevent the mutagen-induced damage of chloroplast DNA.
        
        
          Results
          It was found that the antimutagenicity of the crude Mahonia extract resides in both bis-benzylisoquinoline (BBI) and protoberberine alkaloid fractions but only the protoberberine derivatives, jatrorrhizine and berberine, showed significant concentration-dependent inhibitory effect against the AO-induced chloroplast mutagenesis of E. gracilis. Especially berberine elicited, at a very low dose, remarkable suppression of the AO-induced mutagenicity, its antimutagenic potency being almost three orders of magnitude higher when compared to its close analogue, jatrorrhizine. Possible mechanisms of the antimutagenic action are discussed in terms of recent literature data. While the potent antimutagenic activity of the protoberberines most likely results from the inhibition of DNA topoisomerase I, the actual mechanism(s) for the BBI alkaloids is hard to be identified.
        
        
          Conclusions
          Taken together, the results indicate that berberine possesses promising antimutagenic/anticarcinogenic potential that is worth to be investigated further.
4.17a Facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility: 2010. Number

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility in 2010. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.